Work

OP0182 SECUKINUMAB IN GIANT CELL ARTERITIS: THE RANDOMISED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE PHASE 2 TitAIN TRIAL

Year: 2022

Type: conference-abstract

Source: Annals of the Rheumatic Diseases

DOI: 10.1136/annrheumdis-2022-eular.806

Authors: N. Venhoff, W.A. Schmidt, R. Bergner, J. Rech, L. Unger, H.P. Tony, M. Mendelson, C. Sieder, M. Maricos, J. Thiel

Institutions: University of Freiburg, University Medical Center Freiburg, Immanuel Krankenhaus, Klinikum Ludwigshafen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsklinikum Erlangen, Städtisches Klinikum Dresden, University of Würzburg, Universitätsklinikum Würzburg, Novartis (United States), Novartis (Germany)

Language: English

Topic: Vasculitis and related conditions

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4283588980

Cites:

Cited by: 8

Related to: 10